Daniel S. Levine

Daniel S. Levine is editor of Rare Daily. You can contact him by sending email to editor@globalgenes.org

Gene Therapy Developer Avrobio Closes $60 Million Financing
Rare Daily Staff Gene therapy developer Avrobio said that it has completed a $60 million series B financing, which will be used to advance… Continue Reading
FDA Gives Greenlight to Fibrocell to Begin Enrollment of Pediatric Patients in Trial of Experimental Gene Therapy for Rare Skin Disease
Rare Daily Staff The U.S. Food and Drug Administration gave approval to Fibrocell Science to begin enrolling pediatric patients in a… Continue Reading
FDA Grants MeiraGTx Rare Pediatric Disease Designation to Gene Therapy for Eye Disease
Rare Daily Staff The U. S. Food and Drug Administration granted rare pediatric disease designation to MeiraGTx’s gene therapy product… Continue Reading
Solid Biosciences IPO Raises $133.7 Million, but Former Scientific Advisory Board Member Raises Safety Concerns
Rare Daily Staff Solid Biosciences said it closed its initial public offering of more than 8.9 million shares of common stock at $16 per… Continue Reading
Kevan Chandler is Going Far
Kevan Chandler long dreamed of travelling. The problem was that many of the places he wanted to go weren’t wheelchair accessible. The… Continue Reading
U.S. Food and Drug Administration Orphan Drug Designations in January 2018
Continue Reading
Abeona Receives FDA RMAT Designation for Gene-Corrected Cell Therapy to Treat Epidermolysis Bullosa
Rare Daily Staff The U. S. Food and Drug Administration granted Abeona Therapeutics Regenerative Medicine Advanced Therapy designation for… Continue Reading

Follow us on Twitter